Fredric Eshelman Net Worth
The estimated Net Worth of Fredric N Eshelman is at least $27.2 Million dollars as of 29 January 2018. Fredric Eshelman owns over 335,000 units of G1 Therapeutics stock worth over $26,869,331 and over the last 4 years he sold GTHX stock worth over $0. In addition, he makes $304,973 as Independent Director at G1 Therapeutics.
Fredric Eshelman GTHX stock SEC Form 4 insider trading
Fredric has made over 6 trades of the G1 Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 335,000 units of GTHX stock worth $3,350,000 on 29 January 2018.
The largest trade he’s ever made was buying 621,720 units of G1 Therapeutics stock on 6 December 2016 worth over $20,995,484. On average, Fredric trades about 105,617 units every 33 days since 2015. As of 29 January 2018 he still owns at least 1,273,428 units of G1 Therapeutics stock.
You can see the complete history of Fredric Eshelman stock trades at the bottom of the page.
Fredric Eshelman biography
Dr. Fredric N. Eshelman Pharm.D. is an Independent Director of G1 Therapeutics Inc. Dr. Eshelman has served as a member of our Board of Directors since February 2015. Dr. Eshelman founded Eshelman Ventures, LLC in March 2014, which invests in a variety of companies, primarily in the healthcare sector, and has served as a principal since its founding. Dr. Eshelman served as Chief Executive Officer for Pharmaceutical Product Development, Inc., a contract research organization, from June 1990 to December 2011, as Senior Vice President, Development and a member of the board of directors of the former Glaxo Inc., a pharmaceutical company, from 1989 to 1990. Since September 2015, Dr. Eshelman has served as the chairman of the board of directors of The Medicines Company, a publicly traded biopharmaceutical company. Dr. Eshelman also currently serves as chairman of the board of directors of Eyenovia, Inc., a publicly traded biopharmaceutical company, where he has been a member of the board of directors since December 2014, and he has served on the board of directors of Valeant Pharmaceuticals International, Inc., a publicly traded Canadian pharmaceutical company, since March 2016. Dr. Eshelman previously served on the board of directors of Furiex Pharmaceuticals, a publicly traded biopharmaceutical company, from 2010 until July 2014, when it was sold to Forest Labs/Actavis, and of Pharmaceutical Product Development, Inc., a contract research organization that was publicly traded until 2011, from 1986 until 2011. He also serves on the boards of directors of a number of privately held biopharmaceutical companies. Dr. Eshelman also served on the executive committee of the Medical Foundation of North Carolina, the board of the North Carolina Biotechnology Center, and the Board of Trustees for the University of North Carolina at Wilmington. In addition, Dr. Eshelman serves as an adjunct professor at the University of North Carolina at Chapel Hill School of Pharmacy, where he chairs the Board of Visitors.
What is the salary of Fredric Eshelman?
As the Independent Director of G1 Therapeutics, the total compensation of Fredric Eshelman at G1 Therapeutics is $304,973. There are 11 executives at G1 Therapeutics getting paid more, with John Demaree having the highest compensation of $7,466,410.
How old is Fredric Eshelman?
Fredric Eshelman is 70, he’s been the Independent Director of G1 Therapeutics since 2015. There are no older and 13 younger executives at G1 Therapeutics.
What’s Fredric Eshelman’s mailing address?
Fredric’s mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insider trading at G1 Therapeutics
Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.
What does G1 Therapeutics do?
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
What does G1 Therapeutics’s logo look like?
Complete history of Fredric Eshelman stock trades at G1 Therapeutics, The Medicines Co, and Eyenovia
G1 Therapeutics executives and stock owners
G1 Therapeutics executives and other stock owners filed with the SEC include:
- John Demaree, Chief Commercial Officer
- James Hanson, General Counsel
- Terry Murdock, Chief Operating Officer
- Mark Velleca, President, Chief Executive Officer, Director
- Garry Nicholson, Independent Chairman of the Board
- Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
- Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
- Cynthia Schwalm, Independent Director
- Willie Deese, Independent Director
- Seth Rudnick, Independent Director
- Glenn Muir, Independent Director
- Fredric Eshelman, Independent Director
- Andrew Witty, Independent Director
- Jeff Macdonald, Head of Investor Relations/Public Relations
- Jennifer Moses, Vice President – Finance and Accounting
- Jay Strum, Chief Scientific Officer
- Clay Hatteras Venture Advis…,
- Capital Management, Llcra C…,
- Christy L Shaffer, Director
- Ventures, Inc. Med Immune, 10% owner
- Ventures, Llc Eshelman, 10% owner
- Clay Hatteras Venture Advis…,
- Mark Avagliano, Chief Business Officer